Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Incyte

Incyte is all set to release its fiscal first-quarter earnings later this month, and analysts project a high double-digit profit growth.

Barchart

Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'

Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.

Investors Business Daily

Incyte Scores Relative Strength Rating Upgrade; Hits Key Threshold

Incyte sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Incyte Earns Relative Strength Rating Upgrade; Hits Key Benchmark

Incyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82.

Investors Business Daily

Are Wall Street Analysts Bullish on Incyte Stock?

Incyte has continued to observe strong demand for Jakafi and Opzelura, leading to robust growth in sales, and analysts remain bullish on the stock’s prospects.

Barchart

Incyte Stock Sees Relative Strength Rating Rise To 71

Incyte shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

What You Need to Know Ahead of Incyte's Earnings Release

Biopharma major Incyte is expected to announce its fourth-quarter results later this month and analysts expect a significant double-digit growth in earnings.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Incyte Meets 80-Plus Relative Strength Rating Benchmark

Incyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.

Investors Business Daily

Is Incyte Stock Outperforming the Dow?

Incyte has outperformed the Dow recently, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

Stocks With Rising Relative Price Strength: Incyte

Incyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 81.

Investors Business Daily

Stock Market Rallies After Key Test; Nvidia, Target, Google, Bitcoin In Focus: Weekly Review

The stock market tested key levels but ultimately rallied, with many leaders flashing buy signals. Bitcoin raced toward $100,000.

Investors Business Daily

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.

Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another.

Investors Business Daily

Stocks Flashing Renewed Technical Strength: Incyte

Incyte sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

Incyte Breaks Out To 17-Month High As Jakafi Demand Surges

Incyte stock broke out Tuesday after sales of the company's two key products beat analysts' third-quarter projections.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is Incyte Stock Underperforming the Nasdaq?

Despite Incyte’s underperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Investors Business Daily

Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers

Dow Jones tech giant Intel led the S&P 500 Monday, and kept running late. Apple chipmakers Qorvo and Skyworks sold off on iPhone 16 concerns.

Barchart

Incyte Stock: Is Wall Street Bullish or Bearish?

While Incyte has underperformed the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

StockNews.com

3 Value Stocks With Strong Fundamentals to Buy Now

Value investing is highly favored as it focuses on purchasing undervalued stocks with solid fundamentals, providing the potential for high returns with lower risk and a disciplined, long-term approach. Therefore, it could be wise to invest in fundamentally sound, value stocks Expedia Group (EXPE), Incyte (INCY), and Albertsons Companies (ACI)…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Gems Poised for April Breakthroughs

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more….

Investors Business Daily

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Novartis agreed late Monday to buy MorphoSys for about $2.9 billion. The cancer-focused biotech stock catapulted to a nearly three-year high.

Barchart

2 Best Growth Stocks to Buy with $1,000 Right Now

Growth stocks are getting ready for a comeback year in 2024, and these two under-the-radar stocks have solid financials and significant upside potential.

StockNews.com

3 Biotech Stocks Bursting With Investment Potential

The biotech industry is well-positioned for robust growth thanks to the increasing demand for effective treatments for chronic diseases and the need to serve an aging population. To capitalize on the favorable industry trends, investing in quality biotech stocks Organogenesis Holdings (ORGO), Genmab A/S (GMAB), and Incyte (INCY) could be…

Investors Business Daily

Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival

Incyte stock tumbled to a nearly five-year low Monday after GSK gained FDA approval for a rival myelofibrosis treatment.

Investors Business Daily

Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review

The major indexes retreated for most of the week on banking fears, but rebounded Friday on a strong jobs report and bank stocks roaring back.

Investors Business Daily

Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales

Incyte stock plummeted Tuesday as seasonality hacked at first-quarter revenue and profit with notable sales misses from Jakafi and Opzelura.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.